LLY ▲ +1.2% - Eli Lilly and Company $LLY BREAKS GROUND ON $6.5B HOUSTON PLANT TO MAKE ORAL GLP-1 DRUG FOUNDaYO Eli Lilly has started construction on a roughly 1M-square-foot manufacturing site in Houston, its 10th U.S. manufacturing site announced since 2020. The facility will produce active pharmaceutical ingredients for Foundayo, Lilly’s FDA-approved oral GLP-1 weight-loss pill, along with other small-molecule and advanced medicines. Lilly expects the site to create 615 permanent jobs and about 4,000 construction jobs, with build-out taking roughly five years. The plant is part of Lilly’s broader $50B U.S. manufacturing investment program. Eli Lilly broke ground on a $6.5 billion manufacturing facility in Houston to produce its oral GLP-1 drug Foundayo and other medicines, a move that reflects the company's confidence in demand for its weight-loss pill and broader commitment to U.S. production capacity. The facility, expected to create 615 permanent jobs and support 4,000 construction jobs over a five-year build-out period, represents the company's tenth U.S. manufacturing site announced since 2020 as part of a larger $50 billion domestic investment program. 21-SEP-2026 05:54 PM ET